<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-038332
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051201
<FILING-DATE>20051201
<DATE-OF-FILING-DATE-CHANGE>20051201
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051235913
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v030735_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of December 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 279pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 306pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                December 1, 2005&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em>&#160;</font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">&#160;</td>
              <td align="left" valign="top" width="62%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  launches pSiNutria in the Food
                  Industry</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">-2-</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v030735_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 441pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><IMG SRC="v030735_logo.jpg"></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/Media
        RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #ff0000; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1
        December 2005 </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        launches pSiNutria in the Food Industry</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Applications
        in food quality, safety, authentication</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">and
        detection of bio terrorism</font></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="100%" style="BORDER-BOTTOM: #000000 thin solid">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="100%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that it has created a new spinout company, pSiNutria
        Limited
        to develop applications of our silicon technology in the food industry. pSivida
        will seed fund pSiNutria USD$1.1m (AUD$1.5m) as well as grant pSiNutria a
        royalty bearing exclusive license for the use of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        as an
        ingestible ingredient in food applications. pSiNutria is also developing
        patentable intellectual property using silicon in the food packaging
        area.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSiNutria
        will subsequently seek its own public listing or trade sale. pSivida
        shareholders would receive pSiNutria shares in any future public
        listing.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        will use analysis from Lux Research Inc., the world's leading nanotechnology
        research and advisory firm, to help develop the pSiNutria strategy. In its
        report "Sizing Nanotechnology's Value Chain", Lux Research forecasts $31
        billion
        in nano-enabled products sales in 2005, in applications ranging from
        semiconductors to medical devices to food packaging. Lux also notes that
        food
        industry giants like Kraft, Altria, and Unilever are pursuing nanotechnology
        applications, underscoring this market's promise.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        applications in food primarily pertain to its biodegradability and optical
        properties. BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        dissolves into silicic acid which is found in everyday foods such as beer,
        wine,
        rice and cereals. Potential pSiNutria products being developed includes;
        products to detect pathogens in food, for food tracing, for food preservation,
        and includes products to detect variations of temperature in food storage.
        These
        products may include ingestible BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        which
        will dissolve into silicic acid in the body or silicon used in modified
        atmosphere packaging.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        will prioritise potential products according to value, time to market and
        technical barriers as well as collaborate with potential marketing and
        development partners within the global food industry. There is the potential
        to
        have products on the market within a relatively short time frame given the
        different regulatory environment to therapeutic products.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Greater
        attention is being focused in the food industry on the quality and origin
        of
        food, particularly with concerns from bio terrorism where food sources may
        be
        deliberately contaminated. The ability to detect pathogens, deliberate
        contamination or spoiling of food has enormous commercial value. The USDA
        (United States Department of Agriculture) estimates of the costs of illness
        and
        premature death from the top five food borne pathogens at $6.9 billion in
        the US
        alone. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">US
        and EU
        regulators are looking to smart packaging that sense and even prevent
        disease-causing microbes and viruses. Additionally, food companies are seeking
        to improve the quality of food, in particular the shelf life, traceability
        and
        nutrition, whilst maintaining taste with less salt, sugar, fat and preservatives
        utilising innovative technologies such as those being employed by pSiNutria.
        The
        market for these so-called functional foods is estimated to be about $100
        billion today - a fraction of the $3 trillion global food market, but with
        categories growing at 15-40% annually. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos said, &#8220;pSiNutria is an important part of realising the value in the
        BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        platform
        technology. The food industry is a very different business from drug delivery
        and, like AION Diagnostics our other spinout subsidiary, it will be separately
        staffed with new appointments from the food industry, whilst pSivida maintains
        its core focus on the drug delivery market.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
        update
        on progress made by our other spin out subsidiary, AION Diagnostics, will
        be
        made in the near future.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="justify" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="justify" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="justify" valign="top" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
        and animals. The IP portfolio consists of 29 patent families, 36 granted
        patents
        and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
        as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">),
        the Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">)
        and in Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">.
        pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
        Lynch Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's strategic partner and largest shareholder is QinetiQ, a leading
        international defence, security and technology company, formed in July 2001
        from
        the UK Government's Defence Evaluation &amp; Research Agency (DERA).&#160;
        QinetiQ was instrumental in discovering BioSilicon(TM) and pSivida enjoys
        a
        strong relationship with it having access to its cutting edge research and
        development facilities. For more information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues. Other reasons are contained in
        cautionary statements in the Registration Statement on Form 20-F filed with
        the
        U.S. Securities and Exchange Commission, including, without limitation, under
        Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any
        oral or
        written forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v030735_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v030735_logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0"T`P$1``(1`0,1`?_$`+<``0`#``("`P$`````
M```````'"`D&"@0%`0(#"P$!``$%`0$!`0````````````4#!`8'"`D!`@H0
M```&`@(!`P(#!0<%``````$"`P0%!@<(`!$2$Q0)(0HQ014B(Q9V-V$R0K*V
M%W>14Y6U.!$``@$#`@0#!`4(!@<)`````0(#$00%``8A,1('01,(46%Q(H&1
MH<$4L3)"LB,S%0GPT5)S)#9R4W0U=18Y\6+"DS1$Q'8W_]H`#`,!``(1`Q$`
M/P#O\<::<::<::<::<::K/LOMY@34JM1\]F6YDC9.PN?TVCT"OL75IR=D><.
M/IMH&@4&&(YL-DD7+@Q4O))(&R)SE]95(H^7*\%M-<M2(<!S)X`?$_T.L9W-
MN_`;2MEGS,W3+(:1Q("\TK$T"Q1+5F))`KP4$CJ8:J%$/ODPVP`TZR=U7XY\
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MKB,A'#)JY9LS-W2ZTHNJ_430!JW,W*0WU[`5`'\`$>:L[N=P-P]M]M19_;FV
M\CN>Y:[6*2WLY(HWAA,<LC7,C3$+Y2&-4;Q!D4FBAB+VPM8KR8Q33)".FH+`
MD$U`Z13Q-:_1KC^+LQU?*9)9M&)O8>Q5YP+:?J\P5!.5C3^9DBK`+99PV>,E
M%""4%4CF`#!T8"B(=X?V*]2&Q._,60LL&EUCMX8>8Q7^,O`BW5N0Q3K'EN\<
MT+,"HEC8@-0.$++U7&3Q%UBRC2]+V\@JKK7I/NXT(/N/T:CVU;6T"ER3B,LE
M;R1&*HO'K-%P[J?M6<@9BN9!9>-<.Y%N5ZU,(`8IR!T)#`/T[YIW?OK^[1]L
M\S-A-ZX3>EA-%<S0I)-BQ%#<&!S&\EM)+<Q^=$31E=10HRM0=0U(6NUK^\C$
MEM);L"H-`]2*BM"`#0^[7!+)L8_RW69*HZ^REBH^09Q9G"0^1;+B!QDBK4MU
M)K%;A+RM>C[I7$'!FI#^H3W#PK=,0\U$U2%%,U_VS]>?:3NKN&UP6SL'O.^%
MQ>P6S31XP-;6[SN$1[N>*XE$$*UZY'8?+&&;D-1FXMH[BBQ<RX^\LK3(%"4D
MD!EI3F5B+1];?V06I6E01PU!&-M;\%Z:7!OE'(<U==JMS\CH@TE,U9%&,E\B
MOVRA_2/&4F-<+(5?#N/6ZODBVCXL$0],/3.HX`@B7:O?SU3;([(7&-VUD(;O
M);SS#A;'$V(C-Q*"W1YTK2O''##U`KYDC5=E?H1NB0I@^Q>TUK9W$N?NY7OM
MP%?VV0NN+^)Z(5`(B05(5(Q4+168BFK"YHV+OU5P^DO1L82(;"Y.G5\<X)Q?
M873989BX/FOJIW*Q.8[W"4?C>BQ8KS<\\/XD1CF!TRF]==L138':#>>=[C[9
M.XMT;?R&V)UN'3\+>/%)*T2JA296B/25E+%4'.JD\5H3<[[R4NW+06N#*7N?
MNB(K5!4*TS5JSU_-B@4&69CP"+2O4R@\JU"UFAM4<+1>-&M@D+O;I6;G\A9:
MR5,E\)O*&7KP]&8OM\E4_-0&ZDQ*G\&R`&,#5B@@AY&]/R-LFYN#<R]=**!1
M1[%'(:L]G;8@VEA%QB2&>\>1IKB9N#3W$AK+*WO8\!S(4*"202;/\M]93IQI
MKUTM+Q4#'.I>;D643%LDQ5=R$BY1:-&Z?8!Y*KKG(F3R,(``"/9C"`!V(\AM
MP;BP&T\-/N'<][:X_!6J=<UQ<2)##&O*KR.545)`%34D@"I(&JD4,L\@BA5G
ME;D`*D_0-0XSV6P8_?DC6^188'"JA44U'*,FR9&4,8"E#]1>,4(\I1,/]X50
M+_;SF_&^MOTKY;,+@K3>6.%\[A`9$NH82Q-!_B9H([<"OZ1E"^_4P^V\VD?F
MM;OTT\"I/U`D_9J<4U$U4R*I'(JDJ0JB:B9BG343.4#$.0Y1$IR'*("`@/0A
MSJ6&:*XB6>!E>!U#*RD%64BH92*@@@U!'`CB-0A!!H>!&H7@L^4.Q9(?XKC@
MG/XHCG<RR<"O&%2C/6@@5%]Z;SW)S&(((CX#X!Y?3\.<S;4]6W:C>7>F[["X
M<93_`)[LKF\@D\RW5;;KL0YGZ91*6*_LVZ"8QU<.5=3,^!OK?'+E).C\*P4B
MAXT:E.%/?QXZFOG3NH73C35(=V_D!P'H#6J):\]$O1XO(D]*5RO?P-64K*Y"
M1B(PLL[]^BK*18-6_M#AX&`QQ,;Z=!^/+NTLIKQBL-*CV_\`8?9K!]\=P=O]
MOK6"\S_G^3<.RKY:AC50":U90.8\=6=Q-DNMYGQ?CO+M."1"I9/I59OU9"79
MA'RH0-MAV<Y$A),06<`S?>Q?$]5+S/X'[#R'KOE"6-H96B?\Y20?B.&LFP^5
MM<YB;;-6/5^#N[>.:/J%&Z)%#KU"IH:$5%30ZYM(/V<6P>R<@N1JPCFCE^^=
M*]^FV9LT3N'*ZGB!C>"**9C#T`CT'/P`2:#F=7\DB0QM+(:1JI)/L`%2?H&J
MU:][I:M;6O[/&:[YIJ65G],:1C^T-:T,F*D,SF%G;>,7=_J$<Q+X/%F"Q2^(
MF'M,>^OIRO-:W%N`9E*@\N6L9V]O7:VZY)8MO7D5U)"H+A0PZ0Q(!/4J\R#R
MU:#EOK*=.--.--.-->#*(D<QLBW4336378NT3I*D;J)*D5;J$,FHF[*=JHF<
MINA*H`IB`]&`0[Y%9VVBO<)>6<R))#+:RHR.L;*P:-E*LLH,3*0:%9`8R#1P
M5J-?N)BLJL.!#`^/M]W'ZN.LP,52*4%LO15(I:/*VL<1)0LDC$/*&JS.06$B
M=-,[?'1$(-L)'+)NIXJ$*N8Q/(>P\1YX3]@<W#M7UO[5FP,EFMCFL?<V=REI
M-@7B(-O<E5*;=5+*.DD-O)TR()F=.MJ@H=;-RL9GVW.)0W5&X8%A+7F/&:K'
M@2.!IKB.R.S&(M@'%DJF)K%_%YL!Y.4H%]L4:B"U4_C62K(RKZN0$ZFH=K./
MJRB@5*3%'M-JY4!'R,<IP+T!_-RM98-A[+EE%!)E+Z@\:""#B?8#7AK"NU.Z
M,/N'*Y:SQ$GG?P]HHI7'&/S&ZB41^3%*4>G!20./'5E=#_Z?W/\`G$O_`*2-
MY+?RF?\`\?W-_P#9?_A6VIW?7^\(?[G_`,1U"%\D4K%L?DQY+*1AR0OL*W&M
MY5WCTC4$6R#-`R:33(Z:\6Y.98BI_P!P05B&5$>P`WUY@[MYFWWAZT=[9'<#
MV+Q8SR<?;1W<NWEB"1I#$52+<:R6TA+I)(?(C,R/*QJJN:S5A&;?;MLD755Z
MNQ42UJ:GG#0C@0.)IP]VM*V-/@6M@"VBQ25L)8%"MM'ZQ4S'B(`BB+I>'AR$
M*5&-9/GR":SD$0*+E1%'U!,5!`J?O=8QK;8^&SB54@CC10JA54!5"@!4`4``
M4`4!0."@#6I3:0&];(,.J[*](8\2%K4JM>08T+>+$#JKTK3E7+C5QK(BQ_-I
MI-2,Y9RP/D&0R%0IW7].[A=;79:W#ITV1>T9^RC'4-45XZS2-BL4Y.OY!-*,
M:)QI5G)NQ$"`41"47$7;PI,@4J]*4K7CQX\*#W\=:=N>^6QK'/7VW\@UQ;W-
MAYOF.ZIT,8FZ"L?3(TCL[<$4("WN&O0Z??.+I]N/FQG@>J1>3L=W*R&D"8_<
M9*AJ['PUY<1K9P^6B6#Z!L\_^F6!9@U460:NRI`N"9B)J&6\4C?;K#W5I#Y[
M%63QI7A]8&K;9G?C9F]<[_R]9I=6U\Y(B\Y4"RD`F@*2/1B`2`P`/('J(!G_
M`'UGI1(F/ZRDHJG#NRS<TZ1*)BI/7[(S%HS!;_"I[))TH8H#^`J]_D'/$_\`
MFU;NSUNFT-CP2/'MNY%[>2J"0LT\)@BBZO!O(220@>!FKSIKJ[8D$1-Q<D`S
M#I4>X&I/UT'U:\4^I%.M.%H:R8ZDGDM>'D%&RR3E25;&AYI\NDBI)1!T503;
M1OHG,HDF/F4Z2A`*J(_M=6+_`,O#MMOWTS8O>G9N]N;_`+I7&*MKM)3=1&TO
M)W5&N;1D8+';E&,D<=75HI8PDY;YZ?H;LO+7,O;Y!0MD)&6G2>I0*T;VFO`G
MAQ!X:M7KQ3,@4#';6K9`>QSQW'O%OT4K!ZX?J1\,L1)1*+=N5D$4SF9N15!,
M$Q.0B0E*`]%`.=^^CGMIW>[1=G(-A]WKJRN;^SN7_!"":2=K>S=59;::1T12
M89?-\L1EXTB9(U;I11K%MP7EA?Y`W5@K*K#YJ@"K?V@*^(I6M#7CXZX%3K?@
M=[GB9K]>I#UAE%"2M2<C93QR"39P]:%<#.+%=EEEE#`]`I^A%N7R[_`O?-3]
MM^X_I1RGJNR6SMG[8NK3OI#?91;C(M;HL3SQ";\:XE%V['S@)*'\.O5U<0M=
M7UY:9Q,&EQ<3*V,*I1*\0#3I%.D<N'CJ`YCY4]<Z[O`ST$L->RS"YGD;%$UF
M/FW]8@28[?/Y^HHW*!6;3Q+8I+'9S$>Y301/^G]B[."9@``$P>B@QLYL_P`:
M"IBI6E37@:'PIX'QUH6;NUMNWWV.WMQ%>)FC*J!RB"$EXQ(A#>9UD,&50>C\
MXT-.)U[;>OY/M=/CXE<;06:8S)-@F\I,[%(UZ)QK7X6P/6S&MN(=FX<RZ4Q9
MJY[5.0>3)$FGIBL*IT50'Q\`[^6>.GO@S0]("TYU\?90'^E-5M_=U-M=NIK6
MWSBW,DUVKE!"J-0(5!+=4B4J6^6E:]+>S4*?*CG30?'.*<#6G?37^TY=J]OL
M$DKCVM(U:.FYBH6):JMI*7&89N+G66\>[_2E@;*^FX<AZI!*'T#RY4Q\%W+(
MZ6CA6',^WG[C[]0W=7<.PL5B+&]WY8375K,Q\I`H+1L50L&!EC`/%00&;B/=
M75^<*Y$PM':IXPRK2&B6,M?&&"ZI?*NRFT$XM&B8F:4AG.Q3>5;(O)1-@G7*
MJF0%B$7<`F"0@!S]=C:31S&Z:)_FG+D&GBU:?:=9[@LG@H]H6F8L`+3;:X^.
M:,..GRK<1!U#"K4Z(Z5%32G,ZR#B_N$-"LM3UTQ(JKDS',=.P%I@JGE#(-;B
MXRA3C]:)D&K`7IXV?E;!66DPN)`;+2#%%,/4+[@6X]@$F<)>1!9?E8U'`5K]
MH`/]*5UIR'U%;`S-Q<X;_%6T;12*D\J*(6/20*]+LZ`^!90!^GT\=9V_:Y@(
M9(W``?Q"DXC`?_/7G\P^@\D=R?NXOB?R#6K_`$F_[TS7]Q;_`*\NMOMX/F,U
M#T4N`8ROKRXY"RJDQ:R4M0<8149*OJLRD$4W4:I;I>;F8&#A%Y)HH59%J"ZS
MT4#%5,B5-1,YH6SQ5U>KYB46+VFOV4!UOW?G>G9VP;S^%Y`SW.7H"T,"JS)4
M`CK+NBJ2""%!+4()4`@G\=&_F0U)WMNZF*Z&-WQWE0\<]EH>D9-BHB.7M;"-
M1,ZE#U*8@9N>B)9U&,R&76:G40=@@0ZI$CI)J')]O,5=62^8]&C]HKP^-0-?
MG87>K9^_[TXJP\^UR]"5BG507"BK=#([J2!4E20U`2`0K$:P<C-;>TXTTX(K
MP/+361.9G,`QM:4^SNL1;8N$FK93I!.%OS^QRSN/4<O*Y:Z^SE&5:90E8MD`
MBX<H.V?OE7;!R8HF*`D#R\*/4K9;B]./?S;7=+*7?G76!R@N[6WNKZ^N[C(8
MYKD&D!DQ%K8P,L7FI-"M[<,C2*>*H.O/\/-C-V8"\Q=JZ/;SQR6\K1=`$<G2
M4=25D9@ZD^*J01X'7";O$:U8]P!A3#6LD:QK=*Q^L_*%938.VLPBHZC6Y'<U
M9GCM`JDY9)E\4RKY^=9=5TX,8XG$.N6/\POU+]I/4+L/:EQVZRC7>1M[ZYEN
M+:2&:&>V62&)5$BR($-&!6L4DB5%58BA-OVUV1#L2T;"6-LMOC8XU"=)!ZS4
M]3L1Q9VYLS<2>?LU-NK6;,>8GQY<$[=,&0DW%C&0CX5HS=NY&11+$L42^W!)
M$6J8*+I&)Y*J)E`0^H@'+ST$>I[L]Z?NS6Y(NX>2:+.39LW%O910RRW%R@M(
M$'E]*>4O4ZLG5++&H()8@<=2VZ,+D,KD(3:)6,1T+$@`?,3Q\>7L!U\X`CI;
M)M_M5S;R)$U+-9OXAL+.*L$W&.(.*"4<.$V+X"5"0A)5=4BP$10%^B<4P$1`
M`\A+6](N%W%WP[OY_N99WBI+F\U_$,A#:W]]:R65K^*ED$$P&(GLKIV$@6"`
MW\,AC5BP`+%/F>DBQMA%9LM1%'TJ656#-T@5'[0,O+B>DBOVZ?<]T]:STXTU
MTCM=Z#2,D_<;9>K>0:G7[K7D<Y[*SY(*SQ;29AS3->J]EE(.16C7R:S-PXBI
M)`BZ'J$.!%B%.`>10$,ON)'CP*M&2&Z$Y>_I'Y-<*;;QUAD_4K>6V1ACGM_Q
M]ZW0ZAEZD6=E)4U!Z64,*C@0#X:^OR85&MX6^=;727QI!Q-.&=N>IUW?,JY'
M-(://8G60DZY)2!64>BW:D7EH^%2]T8I`%<XG,?R,<XC^L:S38:02$M0../'
MP/\`7JGW3M+7!=_<9+BHT@,EQ82L$`4%C,J$T6@XA!7AQ))-2==Q3,^'(#,U
M8)!RJRD=)1ZYWL#.-TRJKQCPZ?IJE.B8Q`<L7:8`59+R+Y>)3`(&*40Y!]3/
MIMVCZE]BKM7<$KV6:M)3-87L:AWMIBO2P9"5\V"50%FBZEZNE'5E>-&'H-AL
MQ/AKGSXAU1L*,IY$?<1X'[CK-MRTSSJ7/)K).#FK;QY^RHB9>2I%B\>_W3IN
M;TSQDDJD`_B"#D`_N&.4.Q\4KW'>K/\`EZ[L2Y@F=]CW%SP9"]SA<A2HZ98S
MTFVN&3VB"Y`!,;O&I)V*KX+=<%"*7(7X2)\/:*_$>WCK3##V5(C+],:VJ,1,
MQ<%74CIJ)44*JK%RS<B2B[?U"@7UFZB:Q%$5.B^:9P[`#`8`]O\`TX=_=N>H
MSMI;[^P49M;Q96M[VU9@[6MW&JL\?4*=<;*Z20R44M&Z]2JX=%UOE\7-B+PV
MLIZEI56_M*>1^/@1[?=JBF)__M>V_P`P9*_R/N>4OI]_ZGFXO^,;C_5N=9QE
M?\F0_P!W#]VL*?GVK[[6WY!--MTJXW5;&?HU60DG:0#X.;1@*^Q4V<#F+X_O
M'U2LC1N)1']M-N/Y=\_H`PC">QEM&IX_4PI_7KS@]0]N^V.XN$WO;!@6",:>
M,EI*K<?>R/$M/$+KTV^1V^\?SRZWX-BG'ZW2,>DPI%2`(?OF:E<BX]SL5>UR
M%#R)V\KDF1LH<?IY)E*;Z%Y]L@;/"R3,*.W4?I_-'V@:H]P&3?GJ"QF!@?KL
MK;\,K"E5**OXR7Z3&[*3[0!JS?W17]$=4/\`EN]_Z'2Y:[=_?2?Z(^_66>JS
M_+V+_P!JD_535G=CI5]#?;MLG<>NHV<+Z/:]1*BJ1S)G%C.QV,H231\B"`^#
MF-D%4C!^!BG$!^@\H0@'.D'_`%K_`&=1UD^X9I+?TVQ21FC'!6*_0XMT8?`J
MQ!]QU5GX+M=,(WOXQMB+%?<84F\2M]R!EB$L+JUUR+FUUX2IX_KB<!%MW+YN
MLY9-XMV^<ND!0.F=)TN94ABG`I@NLU<3)D8U1B``.1]K&NL1[!;9P-]VJR-S
MD+6">:XGG5C(BL>E((RB@D5`5F9A0@AC4&M-0#]KC_4?;_\`DC$0?])V\\K[
MD_=Q?$_D&L;])O\`O3-?W%O^O+J[NP6H/Q>Z,[0VC>;<7.4[>[WD.S7O(,/A
M')#&J7]G.3MH=+F0=5O&T35%;!*Q]034]I&+/CC',O!/U50.F0Q;&&[R-W;B
MTM$"HH`ZEJ.0\36E33C3CSUL'<6R^U>Q-U2[\WI?R7.0N9995M9Q',&:1B1T
M0K'U,L9:B%ST*0M6!`.L.\3YGPKF3YQ<`Y?U@QW)X:Q/=<\XT&!J+B$B:HJ`
MNZZE7;;*HUZO/'L-#Q]Q=>Z<BW;JF3$KHXB`&,8H3,L,T6&>.Y8/($/'B?:1
MQ/'AP^K6A<-F\%F>_5CE]J6K6.)FOH.F,JL?,(DA"(2JB0];4!_2/M(U_0`Y
MA&O1'3C3667R`[)Y2/:*%HAJ)*H--M-BHYX]?W4"BX8:W8-:K"RN.;+"*(B=
MK*>`J,X!'Z*+OQ$Y!]0B)%9&R@CZ3>7(_P`,GA_:;P']?]52-5=P=S90W4&P
MMH.!NW(J29.-+2VK22X:G$'FL?(UJ0>ORU>VFM^I>&M8L$U?`-%K3*1JD&FL
M^G9"R,VDM,WNXR?BM9KY<'3M)89:T65^`JKK*>7@7P13\44DR%QG=&!V_O2S
M?&[LL++)8M^<%U!'<0_^7*KKPKSI7QYG6<;0V_9;*Q$6(PA=%C%6DK2260TZ
MY'84JS$?!0`J@*H`K-N?CFBTF'I,A4JK#5UW*S4JWD%8EH5F#E%!@DLDF=)(
M2H`4BAQ$.BASQ1_F9=E^U/;';.V<MV]P&-PU_?9&[2=K2(0B1$AB95*+1``S
M$BBCGK<VS<C?7LTT=W*\BJBD=1K3B?IUX^I-9Q/,P$@-Y@*]/6E]:U6-:823
M0DI+.V3:)8.7AVD6;U1-&,3JB==R=,$$1,`'.`F*`S?\L_LAVF[F=M\]N/?V
MWL9F<M99\0Q2W<(F$<?X2"01]#UCIULS"J$FI\-6F]\W<8S(6]G#.T;S1$JB
MGYFHQ!8`?-0#FWYH\3K2J,B8J$:)Q\-&L(EBEWZ3*-9MV+5,1Z`1(W:II)%$
M>OKT'UY[(8/;V!VQCDQ&VK&TQ^*C_-AMH8X(E^$<2J@Y#D-8++++,_F3,SN?
M$DD_6=>PY,:IZ<::Z*F/M@<5:Q?<#YOR[FJQC4,<Q>>=AX":LYV#Z1:0CBVP
M<]7HA[)H1J#IZE%A*/DBKK$24!`AO,P>`&$,SD@DN,&D<0J_0I^JA^[7`N-W
M%B=K^HN]RV;D,./7(7BL_26"F03(I(4$TZF%2`:#B>`.OVW"S/CW>3YO];93
M7:PH9#I[2^ZT4N/M<.W>A%S"E0MP7*WRD<+MLV<+Q,"R=N`5<>F"9@9JF()D
MP*<5G$]EAY!..EBKFGQ!`^[7S>V9QV_N_&,DVU)^(M4N;*/K4$*?+E5Y&%0#
MTJ&:II^B2*BAUVQ]P+GE^A)UN8I-A=0U0?IJQLLHP8L#N&LZ14Z[0SA^NU7=
M((2#01(0"F(7S0,'XF#OR&_F-]S/49VD@PNY>V&7N,;V[NT:VNVMX(#)%>AF
M>,R7#Q/*B7$)Z8PK*O5`]>+J#Z8;1L\1?F2&]C#W:FJU)H5Y&@!`-#S^.N"Y
M,VKQU?L)2U>6CY!2Z3\.V8+PJ\<<6,;+%4;G5E"29NVQFS-9,5FXD$5C&`H"
M4H]B&J.]_K^[+]VO2_D-GW-I=OW+RV-B@DLGMSY%O=AHRURMR?V9CB=#-;E:
MRDB-71*L5OL;M;(V&:2X5E%G&Y(8'B5X_+3G4\CX<^>N<Z+U^5C<?V><>HJ(
M,+'8DCP_J`)?<MXMD#1R]2*/XH*.CF2`W^(41_(.;5_E5;.S^#[/YO=&5BDA
MQ69RZ&TZ@1YL=K%Y<DR#Q1I7:(-XM"PY`:L=[W$4N0CA0@R1Q_-[BQJ!]7'Z
M=1!B?_[7MO\`,&2O\C[G.7I]_P"IYN+_`(QN/]6YU+Y7_)D/]W#]VJH?<6X1
M-DW00V1&$?[N6P)DZIW9=<A0,LA4[(+F@64@!T)A;^XLC!RKU^!6OD/T*(A[
MWX&81WOEM^:ZD?2./Y*_7KC#U*8)LIV]_B4()GQ]U'+4<^AZQ,/AUO&Q]G37
MPUDO]N;0[#FO<_-FR]]>/K')XKQ)%5U"??F]18]JOYF=8BE%EA+T=9K0Z.^;
M!UT/@H`C_;*[@98+5+>,4#-7Z!Q/VTUIOTRV-UGMZ7VZ,B[2RVEFJ!FY]<M$
M0U]T4<J_#GJX?W17]$=4/^6[W_H=+EEMW]])_HC[]9UZK/\`+V+_`-JD_535
MM,YU&:N_V]3."K[)>0DTM$,(6,&C9,55U&%,K&/[C,'(F4!,?T(>!74$`^O1
M1Y;Q,$SA)_US#ZZ@?:=9;F[.:^].,<$`+2#`6DE!Q^6)(97/T*A/T:S#^'+Y
M&M4M</C[SIAW-F1T*;?V5YR)8:K5@BI>6G,@1]]I4!'0K6G,HMDY"4EAGHQ9
MJH@)T_2$Z1SF*F?S"1R]C<37R31"L9`XU'"A)_(=:K[)=R=J;<[<Y#"YNX\G
M))/*R1]+,T@DA1%"=((+=:,""0`""2`:C[_:Z$.GDK<)-0ADU"4K$A%$S@)3
MIG+/WH#D.4?J4Y#!T(?D(<^[D_=Q?$_D&J?I.!&5S0//R+?]>75*=4LN:T9C
M^4[.&9_E&M4?^D14MDQ_58O):,A)4)O>JO=F\)4:+8(])N^1)7:95$'1(Z,6
M2]@JY:$*J4YA`BMS<Q3PXQ(\<.)I4C@:>WCXDT^LG6&[1S.V<WW<OLQW5E!B
M0S-&DP9HA*KJ$B=0#\D<?6%0CIJBJU>3<ND-@L0[._/E@3+&!Q<*XH=9LP35
M*B[5@QK;60:4:L1=6=2$/"'(BLQ@'+Z-4%D"B2"IFX%,9),1\`^""6WPCQS?
MO.AB?'G4_?J\?<>&W3ZA;'*X"O\`"3>VJ1GIZ`1&L49*KP*K53T@@&E*@'@.
M]_S"]=_:XO>+9'4&E7"]3!5CQ%+J]@MDH1L4#N#QU<B7<P^*W(/0'6,V9F`@
M?F;KGZ1#(X0<V('UZM,A>18ZPGR$]?)@A>1J<^E%+&GOH-9:?$SB>QSF.[GO
MOF=+WVPF],HGE%XY=&]RI1,'G.;_`&6Q?`+*$\V<#'5$&STQ$Q`%A71!4#';
ME-R0R4BAQ9Q?N8A3V5;Q)]]>'QJ1SUJOM'B;F?'3[^S7S;@SK^<36HCMO_;Q
M(:#Y.@!QXE3&&J4!UK)*RL7!1KZ9FY)A#P\6U7?2<K*O&\?&QS%LF95R\?/G
M:B+5HU;I%$QU%#E(0H"(B`<C@"QHHJ3K;<TT-O$T]PZI`@)9F(55`YDDT``\
M2=8H;+[2Q.W@Q=9U+D(J7H=!L4LUOVV-NC)%3`L%(&;)M7%:Q6W0583&PN1D
M!3,)64*8D&U$"F>2:9!$H\/^NGMAVBW7MC`;C[];C;`;`P=Y<SRV]N%;)9-Y
M(D5+.R!KT.Q0^8_ER%$-:(*R+`;8[@YK/WMQBNUEJE[.P"/D9@PL+>AXE:=+
M7<@K\J1E8JT+R4-#9;0MOB&A0=JC&4PW-=INQ,6CFVW^8C%LI9%\F34K=Y)K
ME]HQ;M5)$ZA&4)#HH1463Q101$XG66P#T1^I/L[NC#939V`AV_LO!6^:CML+
MAC/#%>3V[PQ*L\\DK^;D;^ZG+"60&1@W3"M55"V;WFS+G!$7D\MUDLQ-'U75
MY+\SNP)/2`H"0PH/W<,:I&@XA:EB=*.>CVHO3C33C3726UQI]1R']Q1G^CWN
MN0-QJ%FR9MI$V&KV2-93,',QR](M/K,Y&,?I+M72(B4#`!RCXF*!@Z$`$,ON
M':/!(Z$APJ4(Y\UUPOMJQL\EZD,A8Y"*.:QENK]71U#(P,=Q4$$$'79ZUX^,
MS1[57(S_`"S@S`L!3L@O$'[1K8UYFU69S7F,H4R<BRJB-JG9IK5T'J!S)*"Q
M(BH9`PHB;TA$G,<GR%Y<QB*9R4'A0#ZZ`5UU3MSM?L3:>2;+X''QPY%J_.7D
MD*]50>@2.P2H)!Z0#0E:T)&KO2T1%ST<[AYN.9RL6_2%!Y'R#=)TT<I&$!\%
M4%BG3.`&`!`>NRF`!#H0`>8UN';N!W;A;C;FY[.VR&!NXRDUO<1K+%(AXT='
M!4T(!!I56`8$$`ZV'%-+!()H6*2J:@@T(^G4&-]5\#-I`)$E":J*`IZI6SB5
MG',>!^^^ACUY-1H=/O\`P&*8G7TZZYRO9^@GTGV68_C4>TH'G#]0CDNKZ2W!
MK7_T[W+1%?\`N,K)3ATTX:FVW1G6C\LSFGM"J#]86OT\]3ZU:M6+9!FR;(,V
M;5)-NV:M4DT&S=!(H$21002*1-)),@`!2E````Z#G6UA86.*LHL;C(8K;'01
MK'%%$BQQQHHHJ(B`*BJ``JJ``!0#4$SL[%W)+DU)/$D^TG4?Q>(\<PMP=7Z,
MJ[1I;WJ\BZ=39',B==9>6`X2"AD57AV@"Y]0W?28`'?TZYJ/!^GGLUMKN+/W
M:P>#@M^X=S-<2RWHEN"[R774+AC&TS0@R=;5I&`*GI`U?RY;(36@L)92;10`
M%H.2\N-*\/CKSLF8UHV8Z!;<79,KC*W4&]0KNNVRM2)W2;.9AWQ0(Y9K*LEV
MKQ$#@`"4Z2J:I#`!BF`P`/-U1R/$XD0T<'AJ`R>,L<SCY<7DXQ+83H4="2`R
MGPJ""/<000>(-=1-K?J#K=J)#V>!UQQ5"8NBKG*,IFT-HA_/R1YF2C69F#!P
MZ=6&7F'8%:-#F(FF10J9?,P@7R,81J3W4]R0T[=1'+E]VHC;6S]M;/ADM]MV
MJ6L,S!G`9VZBM0*EV8\*F@K3B>''7QLCJ#KAMY#UB`V-Q;$Y0AZ9*/9JLLI:
M3L<82)E)%F$>]=HGKLS#+*G<,R@005,<H`'8``_7B"YGMB3`W23SX`_E!TW+
ML_;>[X8[?<=JMU#"Q9`6=>DFE35&4\:#F2.&I@I^/*50L?US%=4KK"+Q[4JG
M&4:OU4P*R$8QJ4/%(PD=!'+**O5GK%")0*@(.#JF4('1Q-V/=-Y'>0RL:R$U
M)]_.NI>RQMACL;%B+.)4QL,*Q)'Q91&JA%3YJD@**<2:CG75'\9?$[\>^'\L
M)YKH&M%-B+ZSDS3,*X=O[-.5^L2QE#+!)5:G3LY)5.O.VZQO-N=JR3%F8`]O
MZ70=7DF3OI8O)DD)3Z`3\2!76"XOM%VZPV7_`(YC\9"F0#=2DM(Z(W,%(W=H
MT(/%>E1T\.FE-31KKI#JOJ9+W&>UXQ!#8SE\@(L&]P>Q<O:9-2<1BW3]ZP(X
M+89V821!NZDUS@*)4Q$5![[```*,]W<7(`G;J`Y<`/R`:F]M[%VIM"::?;EF
MEK+<!1(0\C=04DJ/G=@*$GE34%95^([X\\U97E<TY%UPKTQ?;!)FFK,[96*[
M5Z%L\RH<%%Y:P5BO66+KLG(/50\W2IVWD\.(F7]0QC"-:/*7T47DI(1'2G('
M[2*Z@<MV?[<YS,-G<EC8WR+OU,0\J*[5J69$=4))XL>GYB26J2=2,I\<6D0Y
M;I6=&NN]*B,I8Y-3S4>RUY>PUI*LA0FZ+6I$C*_`34;6$DH=JW(F4@LA(H0.
ME`/V/=/\==^68BY*-6M:&M>?$BOCJ3/;78W\6@SB8Z&/)VQC,3H70)Y72(Z(
MC+'\H5>!7C3C75VN6FLXU1[?W)F?<,X9@<J8"P\ZS^YI62(&0RKAV*1<.+!>
M,-R$)9H"X,:ZV:M)%PYEHYY+L7P)E:NP,BU/YHG3\PY>620RRF.9NBJ_*WL:
MHI7Z*ZP3N%D]P87"QY7;]F;\P7*M<6X!+RVQ219%0*&)8,R-P5N`)*D5UGO2
M/DOV>R!4Z[CG2[XF\^11H:(C*S!N<Y?IF$<.T1C&,TF+*.2>.VZ*4A$0K5(B
M:;5LNR/Z!`*0"]`7E[)86Z.9+JY0UJ?E^8D^_F03\#K7>.[G;GR-G'C=D[2R
M$?EJL:_B0+:WB50``I*A65!0!0\9H*`#EJ1H#XZMBMK)..NGRA[`?[A5U!XW
ME8[3G`RTK1=<8Q5!8CIHVODBDLVM>556BGXD=J$3*8O7K+)")1I->P6X*6"4
M/]MN+?1X#^G`'4K;=NMQ[JE2^[H9#\1`K!EQ]J6BM%(((\P@AYJ$`\34'AYC
M*::U8;X9Q(TA*]6FF-*,UKM2BD8.K03>KPZ,/78=N'2,9"1J;0K.,9$_[:)"
M%[^HAS56\NTW;'N+?QY/?VW\/FLA"A2.2]M8;EXT)J50S(Y0$\2%I4\ZZW;C
M)'PMHF/Q!-K8Q@!8XOV:*!P`"K0`#X:\AEB3%T<\:2+#'E,9/V#A%VR>-JW$
MHN6CINH55!RW63:E41715*!BF*("40[#F.XST\=AL+DK?,XC9NV;;+6DR303
M18VT26*6-@\<D;K$&1T8!E92"K`$&HU>OELI(ACDN)FC84(+L00>8(KRU(?-
MQZC].--.--0I#ZVZ]5[)CW-$#@W$D+EZ1>2TA(91BL>U1AD!Z_GD%FTX]=V]
MK%)3SAU,-G!TW*AUQ,N0X@<1`1Y6-Q.T?E,[&+V5-.'+ARU!P[8VY;91LW;V
M%FF99F)G6&,3$O4,3(%ZR6!/4:\:FO/4U\HZG-.--.--.--.--.--.--.--.
M--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.
6--.--.--.--.--.--.--.--.--?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
